This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: guideline-directed medical therapy

November 2024 Br J Cardiol 2024;31(4) doi:10.5837/bjc.2024.046 Online First

SGLT2 inhibitors: between the zeal of the clinical studies and the challenges of the day-to-day practice

Mohamed ElRefai, Mohamed Abouelasaad, Alice Zheng, Chitsa Seyani, Amy Greenwood, Hari Johal, Jake Hudson, Claire O’Dowling, Chris Young, Paul Haydock

Abstract

Introduction Dapagliflozin is a well-established treatment for type 2 diabetes mellitus (T2DM) that belongs to a class of medications called sodium-glucose cotransporter type 2 inhibitors (SGLT2i). It exerts its hypoglycaemic effect through reversibly inhibiting SGLT2 in the renal proximal convoluted tubule to reduce glucose re-absorption and increase urinary glucose excretion. Several well-designed randomised-controlled trials were conducted to assess the cardiovascular safety and efficacy of dapagliflozin, when administered at a dose of 10 mg once daily, in reducing cardiovascular events and related hospitalisations associated with heart f

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now